Lenalidomide, p53 and del(5q) Myelodysplastic Syndrome: Ribosome Stress Relief

References (33)

1. 1 Identification of a Primary Target of Thalidomide Teratogenicity [DOI]
2. 2 Identification of RPS14 as a 5q- syndrome gene by RNA interference screen [DOI]
3. 3 Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide [DOI]
4. 4 Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype [DOI]
5. 5 Signaling to p53: Ribosomal Proteins Find Their Way [DOI]
6. 6 TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression [DOI]
7. 7 Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q [DOI]
8. 8 Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells [DOI]
9. 9 A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q– syndrome [DOI]
10. 10 Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma [DOI]
11. 11 Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission [DOI]
12. 12 Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients [DOI]
13. 13 Role for the PP2A/B56δ Phosphatase in Regulating 14-3-3 Release from Cdc25 to Control Mitosis [DOI]
14. 14 A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide [DOI]
15. 15 Ribosomal protein S14 unties the MDM2–p53 loop upon ribosomal stress [DOI]
16. 16 Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study [DOI]
17. 17 Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q− syndrome [DOI]
18. 18 Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion [DOI]
19. 19 Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression [DOI]
20. 20 WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations [DOI]
21. 21 Functional cdc25C Dual-Specificity Phosphatase Is Required for S-Phase Entry in Human Cells [DOI]
22. 22 Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis [DOI]
23. 23 Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion [DOI]
24. 24 Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression [DOI]
25. 25 Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome [DOI]
26. 26 Direct transcriptional regulation of MDM2 by Fli-1 [DOI]
27. 27 Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide [DOI]
28. 28 Non–Diamond Blackfan Anemia Disorders of Ribosome Function: Shwachman Diamond Syndrome and 5q- Syndrome [DOI]
29. 29 Transcription factors Fli1 and EKLF in the differentiation of megakaryocytic and erythroid progenitor in 5q- syndrome and in Diamond–Blackfan anemia [DOI]
30. 30 Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes [DOI]
31. 31 A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q − myelodysplastic syndromes [DOI]
32. 32 The Role of Haploinsufficiency of rps14 and p53 Activation in the Molecular Pathogenesis of the 5q- Syndrome [DOI]
33. 33 Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring [DOI]

Cited by 2

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

• The Role of TNF-Alpha, Beta, XRCC1 and p53 Gene Predisposition in Cancers — shares topic coverage
• P53 and Ki67 Expression by Cervical Cancers in Ile-Ife, Nigeria — shares topic coverage
• In-silico Evaluation of Allium sativum Derived Phytochemicals Reveals Promising Drug Candidates for p53-MDM2 Interaction in Osteosarcoma Therapy — shares topic coverage
• Serum p27, p53, Lactate Dehydrogenase and Alkaline Phosphatase as Candidate Biomarkers in Breast Cancer in Port Harcourt, Nigeria — shares topic coverage
• In vitro Antiproliferative Studies of Selected Medicinal Plants on Cancerous and Normal Cells — shares topic coverage